CCCC C4 Therapeutics
- 5.960
- -0.150-2.45%
C4 Therapeutics News
C4 Therapeutics | 10-Q: Quarterly report
C4 Therapeutics | 8-K: C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
C4 Therapeutics | ARS: Annual Report to Security Holders
C4 Therapeutics | DEFA14A: Others
C4 Therapeutics | DEF 14A: Definitive information statements
C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Mossler Mark
C4 Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-STATE STREET CORPORATION(10.43%),SSGA FUNDS MANAGEMENT, INC.(10.18%)
C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Anderson Kenneth Carl
C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director GROGAN DONNA ROY
C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Dubin Glenn
C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Boyle Scott N
C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Fisher Stewart
C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Schick Kelly
C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Adams Kendra
C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Siegel Jolie
C4 Therapeutics | 8-K: Current report
C4 Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)
C4 Therapeutics | 8-K: Current report
C4 Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
C4 Therapeutics | 10-K: Annual report
Analysis
Price Target
No Data
